Jump Financial LLC Increases Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Jump Financial LLC increased its stake in Teva Pharmaceutical Industries by 172.1%, owning approximately 1.3 million shares valued at $20.37 million as of the last quarter.
• Teva's stock has seen a 1.8% decline recently, with current shares trading around $18.47, well above its one-year low of $12.47.
• Equities analysts are optimistic about Teva, with multiple upgrades resulting in a consensus "Buy" rating and an average target price of $24.71.

Jump Financial LLC increased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 172.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,325,526 shares of the company's stock after purchasing an additional 838,423 shares during the period. Jump Financial LLC owned approximately 0.12% of Teva Pharmaceutical Industries worth $20,373,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mariner LLC boosted its position in shares of Teva Pharmaceutical Industries by 10.6% during the fourth quarter. Mariner LLC now owns 59,356 shares of the company's stock valued at $1,308,000 after buying an additional 5,689 shares during the period. NewEdge Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 12.6% during the 4th quarter. NewEdge Advisors LLC now owns 35,482 shares of the company's stock worth $782,000 after acquiring an additional 3,983 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Teva Pharmaceutical Industries by 13.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,611,743 shares of the company's stock valued at $57,568,000 after acquiring an additional 313,817 shares during the period. MetLife Investment Management LLC boosted its holdings in Teva Pharmaceutical Industries by 40.4% during the 4th quarter. MetLife Investment Management LLC now owns 133,425 shares of the company's stock valued at $2,941,000 after acquiring an additional 38,400 shares during the period. Finally, Stifel Financial Corp grew its position in Teva Pharmaceutical Industries by 33.3% in the 4th quarter. Stifel Financial Corp now owns 88,478 shares of the company's stock valued at $1,950,000 after acquiring an additional 22,087 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president owned 9,989 shares of the company's stock, valued at $170,012.78. The trade was a 38.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric A. Hughes sold 52,742 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,001 shares of company stock valued at $996,958. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Stock Up 0.3%

Teva Pharmaceutical Industries stock traded up $0.06 during mid-day trading on Tuesday, reaching $18.18. 10,831,823 shares of the company were exchanged, compared to its average volume of 13,167,328. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The firm has a market cap of $20.85 billion, a P/E ratio of 7.25, a PEG ratio of 1.07 and a beta of 0.62. The business has a fifty day moving average of $16.79 and a 200 day moving average of $16.29. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. During the same period in the previous year, the company posted $0.61 EPS. The business's revenue for the quarter was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TEVA. Bank of America lifted their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.